MA41642A - Variants de protoxine ii et méthodes d'utilisation - Google Patents

Variants de protoxine ii et méthodes d'utilisation

Info

Publication number
MA41642A
MA41642A MA041642A MA41642A MA41642A MA 41642 A MA41642 A MA 41642A MA 041642 A MA041642 A MA 041642A MA 41642 A MA41642 A MA 41642A MA 41642 A MA41642 A MA 41642A
Authority
MA
Morocco
Prior art keywords
protoxin
variants
methods
Prior art date
Application number
MA041642A
Other languages
English (en)
Inventor
Mack Flinspach
Alan Wickenden
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA41642A publication Critical patent/MA41642A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
MA041642A 2015-03-03 2016-02-24 Variants de protoxine ii et méthodes d'utilisation MA41642A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562127339P 2015-03-03 2015-03-03

Publications (1)

Publication Number Publication Date
MA41642A true MA41642A (fr) 2018-01-09

Family

ID=56849056

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041642A MA41642A (fr) 2015-03-03 2016-02-24 Variants de protoxine ii et méthodes d'utilisation

Country Status (15)

Country Link
US (3) US20160257726A1 (fr)
EP (1) EP3265476A4 (fr)
JP (2) JP2018512123A (fr)
KR (1) KR20170120703A (fr)
CN (1) CN107531769A (fr)
AR (1) AR103838A1 (fr)
AU (2) AU2016226443B2 (fr)
BR (1) BR112017018834A2 (fr)
CA (1) CA2978435A1 (fr)
HK (1) HK1249118A1 (fr)
IL (2) IL254273A0 (fr)
MA (1) MA41642A (fr)
MX (1) MX2017011223A (fr)
TW (1) TW201706292A (fr)
WO (1) WO2016140859A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
ES2841173T3 (es) 2013-10-03 2021-07-07 Janssen Biotech Inc Variantes de Protoxina-II y métodos de uso
EP3236882B1 (fr) 2014-12-23 2020-02-05 Automed Pty Ltd Appareil d'administration, système et procédés associés
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
KR20170134542A (ko) 2015-04-02 2017-12-06 얀센 바이오테크 인코포레이티드 프로톡신-ii 변이체 및 사용 방법
CN109369785B (zh) * 2018-11-14 2019-08-30 青海芬陀利华生物科技有限公司 Ccotx1毒素及其应用
CN109369784B (zh) * 2018-11-14 2019-08-30 青海芬陀利华生物科技有限公司 PaTx-1毒素及其应用
US11957542B2 (en) * 2020-04-30 2024-04-16 Automed Patent Holdco, Llc Sensing complete injection for animal injection device
CN114957431B (zh) * 2022-06-27 2023-06-20 四川丽妍工坊生物科技有限公司 一种皮肤抗皱多肽Cj2a2、制备方法及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
CA2285658C (fr) 1997-04-16 2011-10-04 Nozar M. Mehta Expression directe de peptides dans un milieu de culture
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
ES2340857T3 (es) 1997-09-16 2010-06-10 Centocor Ortho Biotech Inc. Metodo para la sintesis quimica completa y emsamblaje de genes y genomas.
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
EP1348466A3 (fr) 2002-02-01 2003-10-29 Inspire Pharmaceuticals, Inc. Méthode de traitement du douleur avec adenosine tetraphosphates
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
WO2007056326A2 (fr) 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions et methodes pour inhiber l'expression du gene nav1.8
WO2007109324A2 (fr) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Bloqueurs puissants et sélectifs du canal sodique nav1.7
CA2662453A1 (fr) 2006-09-08 2008-03-13 Mayo Foundation For Medical Education And Research Polypeptides aquaretiques et natriuretiques depourvus d'activite vasodilatatoire
WO2008033564A1 (fr) 2006-09-15 2008-03-20 Hydra Biosciences Inc. Composés permettant de moduler la fonction du trpv3
US8043829B2 (en) 2006-10-25 2011-10-25 Amgen Inc. DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
WO2010028089A2 (fr) 2008-09-03 2010-03-11 Arbor Vita Corporation Agents et méthodes de traitement de la douleur
WO2010104115A1 (fr) 2009-03-10 2010-09-16 独立行政法人産業技術総合研究所 Procédé de préparation d'un polypeptide reconnaissant de façon spécifique une protéine membranaire
AU2010296994B2 (en) 2009-09-15 2013-09-19 Alomone Preclinical Ltd. Novel peptides isolated from spider venom, and uses thereof
US9279003B2 (en) * 2010-07-07 2016-03-08 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
CN101979411A (zh) 2010-10-21 2011-02-23 湖南师范大学 虎纹捕鸟蛛蛋白酶抑制剂
EA201370161A1 (ru) 2011-01-18 2013-12-30 Амген Инк. НОКАУТНЫЕ ПО Na1.7 МЫШИ И ИХ ПРИМЕНЕНИЕ
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
CN110041420A (zh) 2012-05-18 2019-07-23 詹森生物科技公司 虎纹捕鸟蛛毒素-iv变体及其使用方法
US9102751B2 (en) * 2012-05-18 2015-08-11 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
US9718865B2 (en) 2012-07-27 2017-08-01 Purdue Pharma L.P. Sodium channel blocking peptides and the use thereof
UY35397A (es) 2013-03-12 2014-10-31 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
CN104065367B (zh) 2013-03-20 2017-11-07 江苏多维科技有限公司 一种低功耗磁电阻开关传感器
ES2841173T3 (es) 2013-10-03 2021-07-07 Janssen Biotech Inc Variantes de Protoxina-II y métodos de uso
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
KR20170134542A (ko) 2015-04-02 2017-12-06 얀센 바이오테크 인코포레이티드 프로톡신-ii 변이체 및 사용 방법

Also Published As

Publication number Publication date
JP2018512123A (ja) 2018-05-17
CA2978435A1 (fr) 2016-09-09
JP2022071050A (ja) 2022-05-13
US10995125B2 (en) 2021-05-04
IL254273A0 (en) 2017-10-31
BR112017018834A2 (pt) 2018-04-17
TW201706292A (zh) 2017-02-16
AR103838A1 (es) 2017-06-07
MX2017011223A (es) 2018-06-20
HK1249118A1 (zh) 2018-10-26
IL282482A (en) 2021-06-30
AU2016226443B2 (en) 2020-10-22
WO2016140859A2 (fr) 2016-09-09
US20210363204A1 (en) 2021-11-25
US20160257726A1 (en) 2016-09-08
AU2016226443A1 (en) 2017-09-21
WO2016140859A3 (fr) 2016-10-27
CN107531769A (zh) 2018-01-02
EP3265476A2 (fr) 2018-01-10
EP3265476A4 (fr) 2018-08-22
KR20170120703A (ko) 2017-10-31
AU2021200400A1 (en) 2021-03-18
US20170334959A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
MA43284A (fr) Composés et leurs méthodes d'utilisation
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
MA42302A (fr) Lactames bicycliques et leurs méthodes d'utilisation
MA49715A (fr) Oligomères et conjugués d'oligomères
DK3291679T3 (da) Ændring af mikrobielle populationer og modificering af mikrobiota
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA41642A (fr) Variants de protoxine ii et méthodes d'utilisation
DK3331876T3 (da) Modulators of ror-gamma
MA43385A (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
MA44526A (fr) Oxystérols et leurs méthodes d'utilisation
MA41864A (fr) Variants de protoxine ii et leurs méthodes d'utilisation
MA42118A (fr) Benzamides substitués et leurs méthodes d'utilisation
MA44087A (fr) Immunothérapie basée sur la listéria et ses méthodes d'utilisation
MA46422A (fr) Oligonucléotides modifiés et méthodes d'utilisation
MA39915B1 (fr) Composés de pladiénolide pyridine et leurs procédés d'utilisation
MA43282A (fr) Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
DK3307267T3 (da) Behandling af multipel sklerose
DK3316951T3 (da) Eyewear and flexible elements
MA44862A (fr) Formulations de fulvestrant et méthodes d'utilisation de celles-ci
MA49905A (fr) Polyesteramines et polyesterquats
DK3328395T3 (da) Ny brug af dextransulfat
MA42683A (fr) Composés thérapeutiques et leurs méthodes utilisation